US Department of Defense funds MediWound’s non-surgical burn treatment
Biotherapeutics company MediWound has secured an additional $6.7 million in funding from the US Department of Defense to advance its non-surgical burn treatment for the US Army.
Biotherapeutics company MediWound has secured an additional $6.7 million in funding from the US Department of Defense to advance its non-surgical burn treatment for the US Army.
Novo Nordisk is set to open a new AI research hub in Kings Cross’ Knowledge Quarter, a cluster of leading science institutions and companies.
AstraZeneca and Sanofi’s respiratory syncytial virus (RSV) vaccine for infants has received approval for use in China.